Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Peter Ellis, MD, MPH and Lydia S. Dugdale, MD, MAR
Presenting all, including expensive, options to all patients means advocating not only for individual patients, but also for a just health care system.
AMA J Ethics. 2019;21(1):E26-31. doi:
10.1001/amajethics.2019.26.
Weyinshet Gossa, MD, MPH and Michael D. Fetters, MD, MPH, MA
Cervical cancer has become rare in high-income countries but is a leading cause of mortality among women in low- and middle-income countries. This inequity is an epidemiological tragedy.
AMA J Ethics. 2020;22(2):E126-134. doi:
10.1001/amajethics.2020.126.